AbbVie, Tolero team up to test Venclexta combo in AML

Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s BCL-2 blocker Venclexta in relapsed/refractory acute myeloid leukemia (AML). The pair will equally share development costs.